Roux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years - Takeaways - MDSpire

Roux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years

  • By

  • Sibi Thiyagarajan

  • Elizabeth Wall-Wieler

  • Yuki Liu

  • Feibi Zheng

  • Michael Edwards

  • January 3, 2026

  • 0 min

Share

  • 1

    Roux-en-Y gastric bypass (RYGB) and GLP-1 receptor agonists (GLP-1 RAs) are effective treatments for severe obesity and type 2 diabetes.

  • 2

    RYGB is associated with greater weight loss and higher diabetes resolution rates compared to GLP-1 RAs, but typically incurs higher out-of-pocket costs.

  • 3

    The study analyzed out-of-pocket healthcare costs for commercially insured patients undergoing RYGB versus GLP-1 RAs over two years.

  • 4

    New GLP-1 RAs may have reduced out-of-pocket costs for patients, impacting the financial considerations of treatment choices.

  • 5

    The findings aim to facilitate data-driven discussions between obesity care providers and patients regarding treatment options.

Original Source(s)

Related Content